お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:肥満:消化管ホルモン受容体は商業的な注目を浴びる
市場調査レポート
商品コード
865065

肥満:消化管ホルモン受容体は商業的な注目を浴びる

Obesity: Gut Hormone Receptors Retain Commercial Prominence

出版日: | 発行: GlobalData | ページ情報: 英文 46 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
肥満:消化管ホルモン受容体は商業的な注目を浴びる
出版日: 2019年05月31日
発行: GlobalData
ページ情報: 英文 46 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の肥満市場について調査し、疾病の概要、パイプラインの分析・比較と開発段階・分子タイプ・分子標的別による階層化、およびファーストインクラス標的の治療潜在性の評価などを提供しています。

第1章 目次

第2章 肥満:エグゼクティブサマリー

第3章 イントロダクション

第4章 疾病の概要

  • 病因と病態生理学
  • 分類または病期システム
  • 肥満における持続したイノベーション
  • 肥満の疫学
  • 上市薬の概要

第5章 パイプライン製品イノベーションの評価

  • 概要
  • パイプライン:開発段階・分子タイプ別
  • パイプライン:分子標的別
  • 肥満市場とパイプライン間のプログラムの比較分布:治療標的ファミリー別
  • ファーストインクラスと非ファーストインクラスパイプラインプログラムの比較分布:分子標的クラス別
  • パイプラインにおけるファーストインクラス分子標的に対するファーストインクラスプログラム比率

第6章 ファーストインクラス分子標的の評価

  • 概要
  • BMPR2を標的としたパイプラインプログラム
  • BMPR1Aを標的としたパイプラインプログラム
  • FADS1を標的としたパイプラインプログラム
  • BMPR1Bを標的としたパイプラインプログラム
  • SLC27A2を標的としたパイプラインプログラム
  • SREBF1を標的としたパイプラインプログラム
  • ADIPOQを標的としたパイプラインプログラム
  • C3AR1を標的としたパイプラインプログラム
  • ACACBを標的としたパイプラインプログラム

第7章 主要企業・契約

第8章 付録

図表

List of Tables

  • Table 1: Nutritional status
  • Table 2: Obesity Total Prevalent Cases (Millions), 2012-2022

List of Figures

  • Figure 1: Obesity, Global Market by Molecular Target and Molecule Type, 2019
  • Figure 2: Obesity, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 3: Obesity Global Pipeline, by Molecular Target and Stage of Development, 2019
  • Figure 4: Obesity, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 5: Obesity, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 6: Obesity, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 7: Obesity, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
目次
Product Code: GDHC496FP

Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline.

Scope

  • The obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets. Which drug classes are used to treat this disease? How do the drug classes in the market compare with those in the pipeline?
  • There are 267 pipeline programs in active development for obesity, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class obesity pipeline? Which first-in-class targets have been identified as most promising for obesity, and is there any overlap?
  • Which companies are the key players within the obesity market? Who has been involved in the most licensing and co-development deals for obesity products? Which first-in-class products have prior deal involvement?

Reasons to buy

  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for obesity.
  • Visualize the composition of the obesity markets in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze and compare the obesity pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class obesity pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for obesity first-in-class products.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Obesity: Executive Summary

  • 2.1 The Need for Further Novel Therapies
  • 2.2 Pipeline Shows Increasing Innovation
  • 2.3 Deals Landscape presents Investment Opportunities

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Sustained Innovation in Obesity
  • 4.4 Epidemiology for Obesity
  • 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

  • 5.1 Overview
  • 5.2 Pipeline by Stage of Development and Molecule Type
  • 5.3 Pipeline by Molecular Target
  • 5.4 Comparative Distribution of Programs Between Obesity Market and Pipeline by Therapeutic Target Family
  • 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
    • 5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
  • 5.6 Ratio of First-in-Class Products to First-in-Class Molecular Target within the Pipeline

6 First-in-Class Molecular Target Evaluation

  • 6.1 Overview
  • 6.2 Pipeline Programs Targeting BMPR2
  • 6.3 Pipeline Programs Targeting BMPR1A
  • 6.4 Pipeline Programs Targeting FADS1
  • 6.5 Pipeline Programs Targeting BMPR1B
  • 6.6 Pipeline Programs Targeting SLC27A2
  • 6.7 Pipeline Programs Targeting SREBF1
  • 6.8 Pipeline Programs Targeting ADIPOQ
  • 6.9 Pipeline Programs Targeting C3AR1
  • 6.10 Pipeline Programs Targeting ACACB

7 Key Players and Deals

  • 7.1 Overview
    • 7.1.1 Zafgen Licensing Deal with Children's Medical Center Corporation
    • 7.1.2 Diasome Pharmaceuticals Signs Licensing Deal with SDG
    • 7.1.3 Evotec Co-development Deal with Eternygen

8 Appendix

  • 8.1 Bibliography
  • 8.2 Abbreviations
  • 8.3 Methodology
    • 8.3.1 Market Analysis
    • 8.3.2 Overall Pipeline Analysis
    • 8.3.3 First-in-Class Pipeline Analysis
    • 8.3.4 First-in-Class Matrix Assessment
    • 8.3.5 First-in-Class Molecular Target Evaluation
    • 8.3.6 Key Players and Deals
  • 8.4 About the Authors
    • 8.4.1 Analyst
    • 8.4.2 Therapy Area Director
    • 8.4.3 Global Director of Therapy Analysis and Epidemiology
    • 8.4.4 Global Head and EVP of Healthcare Operations and Strategy
  • 8.5 About GlobalData
  • 8.6 Contact Us
  • 8.7 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.